^
Association details:
| Biomarker: | MLL2 mutation |
|---|---|
| Cancer: | Solid Tumor |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
The potential biomarkers of checkpoint inhibitor immunotherapy in solid malignancies.
Published date:
05/25/2020
Excerpt:
18 pts with various tumor types (Table) had PD. Most of IOs were given as 2nd or 3rd line setting in NR group. Most common gene alterations were MLL2 (33.3%), CDKN2A/B (27.8%), NTRK1 (27.8%), ARID1B (22.2%) in 18 patients.
DOI:
10.1200/JCO.2020.38.15_suppl.e15226
